FDA Approved: VELCADE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Velcade (bortezomib) filed by Takeda Pharmaceuticals America, Inc., expanding or modifying its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

SUPPL AP for VELCADE (BORTEZOMIB)